A number of investment brokers have recently updated their price targets on shares of Biogen Idec Inc. (NASDAQ:BIIB).

Most recent broker ratings

05/03/2016 – Biogen Idec Inc. had its “market perform” rating reiterated by analysts at Leerink Swann. They now have a USD 319 price target on the stock.

04/21/2016 – Biogen Idec Inc. had its “hold” rating reiterated by analysts at Stifel Nicolaus.

04/11/2016 – Biogen Idec Inc. had its “buy” rating reiterated by analysts at Citigroup. They now have a USD 345 price target on the stock.

04/06/2016 – Biogen Idec Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 325 price target on the stock.

04/05/2016 – BMO Capital Markets began new coverage on Biogen Idec Inc. giving the company a “market perform” rating. They now have a USD 283 price target on the stock.

03/11/2016 – Biogen Idec Inc. had its “neutral” rating reiterated by analysts at Robert W. Baird. They now have a USD 268 price target on the stock.

01/28/2016 – Biogen Idec Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 360 price target on the stock.

01/22/2016 – Biogen Idec Inc. had its “overweight” rating reiterated by analysts at Barclays. They now have a USD 420 price target on the stock.

01/21/2016 – Biogen Idec Inc. had its “outperform” rating reiterated by analysts at Wells Fargo.

01/20/2016 – Credit Suisse began new coverage on Biogen Idec Inc. giving the company a “neutral” rating. They now have a USD 322 price target on the stock.

01/07/2016 – Biogen Idec Inc. had its “buy” rating reiterated by analysts at Standpoint Research.

01/04/2016 – Biogen Idec Inc. had its “outperform” rating reiterated by analysts at Cowen. They now have a USD 368 price target on the stock.

12/18/2015 – Atlantic Equities began new coverage on Biogen Idec Inc. giving the company a “overweight” rating. They now have a USD 344 price target on the stock.

12/01/2015 – Biogen Idec Inc. had its “strong buy” rating reiterated by analysts at Raymond James. They now have a USD 104 price target on the stock.

11/05/2015 – Biogen Idec Inc. was upgraded to “overweight” by analysts at Piper Jaffray. They now have a USD 307 price target on the stock.

The share price of Biogen Idec Inc. (NASDAQ:BIIB) was down -0.38% during the last trading session, with a day high of 265.87. 1202308 shares were traded on Biogen Idec Inc.’s last session.

The stock’s 50 day moving average is 267.65 and its 200 day moving average is 275.47. The stock’s market capitalization is 57.64B. Biogen Idec Inc. has a 52-week low of 242.07 and a 52-week high of 420.99.

View other investors thoughts on Biogen Idec Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.